MiR-22 Modulates Lenalidomide Activity by Counteracting MYC Addiction in Multiple Myeloma.

ABSTRACT: Background: MYC is a master regulator of multiple myeloma (MM) by orchestrating several pro-tumoral pathways, including reprograming of the miRNA transcriptome. MYC is also involved in the acquirement of resistance to anti-MM drugs, including immunomodulatory imide drugs (IMiDs). Methods: In silico analysis was performed on MM proprietary and on public MMRF-CoMMpass datasets. Western blot and chromatin immunoprecipitation (ChIP) experiments were performed to validate miR-22 repression induced by MYC. Cell viability and apoptosis assays were used to evaluate lenalidomide sensitization after miR-22 overexpression. Results: We found an inverse correlation between MYC and miR-22 expression, which is associated with poor outcome in IMiD-treated MM patients. Mechanistically,

SUBMITTER: Caracciolo D 

PROVIDER: S-EPMC8431372 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature